

This symposium was approved by the 16<sup>th</sup> World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the 16<sup>th</sup> World Conference on Lung Cancer. This symposium is not sponsored or endorsed by the International Association for the Study of Lung Cancer.



This activity is provided by prIME Oncology.

# Transforming Advanced Lung Cancer Into a Chronic Disease: *Answering Key Questions*

## Chair

**Paul A. Bunn, Jr, MD**

University of Colorado Denver  
Denver, Colorado, United States

## Faculty

**Joel Neal, MD, PhD**

Stanford University Medical Center  
Stanford, California, United States

**Suresh Ramalingam, MD**

Emory University  
Winship Cancer Institute  
Atlanta, Georgia, United States

## Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.



prIME Oncology designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Monday, September 7, 2015**

**6.30 AM – 7.00 AM Registration and Breakfast**

**7.00 AM – 8.00 AM Educational Session**

**Room 205+207**

Colorado Convention Center  
Denver, Colorado

## Agenda

**Welcome and introduction**

*Paul A. Bunn, Jr, MD*

**7.00 AM Is non-small cell lung cancer (NSCLC) becoming a chronic disease?**

*Paul A. Bunn, Jr, MD*

**7.15 AM Ask the experts**

**7.20 AM What are the best strategies to overcome acquired tyrosine kinase inhibitor resistance?**

*Suresh Ramalingam, MD*

**7.35 AM Ask the experts**

**7.40 AM When should an immunotherapeutic approach be considered in NSCLC management?**

*Joel Neal, MD, PhD*

**7.55 AM Ask the experts**

**8.00 AM Concluding remarks and adjourn**

*Paul A. Bunn, Jr, MD*

This educational activity is supported by a grant from AstraZeneca.